Published in PLoS Med on March 27, 2012
Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. N Engl J Med (2016) 1.73
Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med (2014) 1.69
Comparison of an assumed versus measured leucocyte count in parasite density calculations in Papua New Guinean children with uncomplicated malaria. Malar J (2014) 1.07
Severe anemia in Papua New Guinean children from a malaria-endemic area: a case-control etiologic study. PLoS Negl Trop Dis (2012) 1.00
High levels of genetic diversity of Plasmodium falciparum populations in Papua New Guinea despite variable infection prevalence. Am J Trop Med Hyg (2013) 0.96
Use of antibiotics within the IMCI guidelines in outpatient settings in Papua New Guinean children: an observational and effectiveness study. PLoS One (2014) 0.96
The effect of iron-fortified complementary food and intermittent preventive treatment of malaria on anaemia in 12- to 36-month-old children: a cluster-randomised controlled trial. Malar J (2015) 0.94
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. PLoS Med (2012) 0.94
Global Epidemiology of Plasmodium vivax. Am J Trop Med Hyg (2016) 0.93
Plasmodium malaria and antimalarial antibodies in the first year of life. Parasitology (2016) 0.89
Impact of Placental Malaria and Hypergammaglobulinemia on Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea. J Infect Dis (2015) 0.80
Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea. Malar J (2015) 0.80
Plasmodium falciparum and Plasmodium vivax genotypes and efficacy of intermittent preventive treatment in Papua New Guinea. Antimicrob Agents Chemother (2014) 0.80
Biochemical and functional characterization of Plasmodium falciparum GTP cyclohydrolase I. Malar J (2014) 0.80
Malaria and severe anemia: thinking beyond Plasmodium falciparum. PLoS Med (2013) 0.79
Selective intermittent preventive treatment of vivax malaria: reduction of malaria incidence in an open cohort study in brazilian Amazon. Malar Res Treat (2013) 0.79
Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life. PLoS One (2016) 0.77
Peripheral blood mononuclear cells derived from grand multigravidae display a distinct cytokine profile in response to P. falciparum infected erythrocytes. PLoS One (2014) 0.75
Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev (2004) 28.04
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis (2009) 5.90
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med (2008) 5.29
Indoor residual spraying for preventing malaria. Cochrane Database Syst Rev (2010) 5.28
A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med (2008) 4.77
Plasmodium vivax resistance to chloroquine? Lancet (1989) 4.51
Intermittent presumptive treatment for malaria. PLoS Med (2005) 3.36
Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev (2009) 3.26
Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis (2007) 2.66
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J (2009) 2.64
Drugs for preventing malaria in pregnant women. Cochrane Database Syst Rev (2006) 2.43
Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc Natl Acad Sci U S A (2001) 2.41
Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg Infect Dis (2010) 2.24
High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One (2009) 2.18
From evidence to action? Challenges to policy change and programme delivery for malaria in pregnancy. Lancet Infect Dis (2007) 2.05
The epidemiology of malaria in Papua New Guinea. Trends Parasitol (2003) 2.03
Plasmodium vivax in Africa: hidden in plain sight? Trends Parasitol (2007) 2.02
Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis (2009) 1.95
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg (2004) 1.88
Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One (2010) 1.87
Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol (2004) 1.80
A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One (2011) 1.76
Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol (2007) 1.71
The IPTi Consortium: research for policy and action. Trends Parasitol (2006) 1.61
Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg (2007) 1.58
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother (2009) 1.52
Multilocus haplotypes reveal variable levels of diversity and population structure of Plasmodium falciparum in Papua New Guinea, a region of intense perennial transmission. Malar J (2010) 1.47
The hypnozoite and malarial relapse. Prog Clin Parasitol (1989) 1.32
Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J (2009) 1.26
Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis (2008) 1.26
Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther (2010) 1.23
The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS One (2010) 1.22
Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial. PLoS One (2010) 1.14
Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children. PLoS One (2011) 1.12
Patterns of growth in height and weight from birth to eighteen years of age. Pediatrics (1959) 1.12
Effect of a large dam on malaria risk: the Koka reservoir in Ethiopia. Trop Med Int Health (2007) 1.11
Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar J (2008) 1.10
Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Antimicrob Agents Chemother (2004) 1.10
Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malar J (2009) 1.09
Chemoprophylaxis and intermittent treatment for preventing malaria in children. Cochrane Database Syst Rev (2008) 1.08
Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers. Antimicrob Agents Chemother (2011) 1.06
Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS One (2010) 1.04
The Chesson strain of Plasmodium vivax malaria; relationship between prepatent period, latent period and relapse rate. J Infect Dis (1947) 1.00
Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in Papua New Guinea using an extended ligase detection reaction fluorescent microsphere assay. Antimicrob Agents Chemother (2010) 0.97
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J Infect Dis (2008) 0.95
Community effectiveness of intermittent preventive treatment for infants (IPTi) in rural southern Tanzania. Am J Trop Med Hyg (2010) 0.93
Community response to intermittent preventive treatment of malaria in infants (IPTi) in Papua New Guinea. Malar J (2010) 0.92
Assessment of the origins and spread of putative resistance-conferring mutations in Plasmodium vivax dihydropteroate synthase. Am J Trop Med Hyg (2009) 0.90
Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. Antimicrob Agents Chemother (2011) 0.80
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet (2004) 9.24
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis (2002) 5.75
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med (2008) 5.29
A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med (2008) 4.77
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
Mass treatment with single-dose azithromycin for yaws. N Engl J Med (2015) 3.84
Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes. Cell (2008) 3.80
Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet (2005) 3.79
Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. Nat Med (2002) 3.29
Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis (2006) 3.17
Reported reasons for not using a mosquito net when one is available: a review of the published literature. Malar J (2011) 3.16
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg (2004) 3.00
A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria. Nature (2005) 2.99
Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis (2008) 2.80
Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A (2010) 2.79
Clinical features and pathogenesis of severe malaria. Trends Parasitol (2004) 2.73
The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg (2007) 2.72
The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med (2010) 2.61
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol (2003) 2.52
New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis (2012) 2.52
Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. Am J Trop Med Hyg (2006) 2.42
Super-resolution dissection of coordinated events during malaria parasite invasion of the human erythrocyte. Cell Host Microbe (2011) 2.37
Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis (2009) 2.36
Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS (2006) 2.34
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS One (2008) 2.29
Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci U S A (2010) 2.25
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci U S A (2003) 2.19
Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. Clin Infect Dis (2012) 2.19
Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int J Parasitol (2008) 2.19
Randomized controlled safety and efficacy trial of 2 vitamin A supplementation schedules in Tanzanian infants. Am J Clin Nutr (2007) 2.11
The global distribution of the Duffy blood group. Nat Commun (2011) 2.06
Levels and trends of demographic indices in southern rural Mozambique: evidence from demographic surveillance in Manhiça district. BMC Public Health (2006) 2.05
Plasmodium malariae and Plasmodium ovale--the "bashful" malaria parasites. Trends Parasitol (2007) 2.04
The future for blood-stage vaccines against malaria. Immunol Cell Biol (2009) 2.04
Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun (2003) 2.02
Molecular evidence for the localization of Plasmodium falciparum immature gametocytes in bone marrow. Blood (2013) 2.01
The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS (2004) 2.01
R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A (2003) 2.00
Accuracy and reliability of malaria diagnostic techniques for guiding febrile outpatient treatment in malaria-endemic countries. Am J Trop Med Hyg (2008) 1.98
Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science (2012) 1.97
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest (2008) 1.96
Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem (2005) 1.95
Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis (2009) 1.95
Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med (2007) 1.95
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand. Proc Natl Acad Sci U S A (2010) 1.91
Rise in malaria incidence rates in South Africa: a small-area spatial analysis of variation in time trends. Am J Epidemiol (2002) 1.88
Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. Malar J (2009) 1.87
Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One (2010) 1.87
Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum. Mol Cell Proteomics (2006) 1.86
Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis (2006) 1.82
MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol (2003) 1.82
Identification of a conserved Plasmodium falciparum var gene implicated in malaria in pregnancy. J Infect Dis (2002) 1.81
Malaria in pregnancy and the endemicity spectrum: what can we learn? Trends Parasitol (2004) 1.81
Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol (2004) 1.80
Improved laboratory capacity is required to respond better to future cholera outbreaks in Papua New Guinea. Western Pac Surveill Response J (2012) 1.79
Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis (2010) 1.79
Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol (2006) 1.78
VAR2CSA is the principal ligand for chondroitin sulfate A in two allogeneic isolates of Plasmodium falciparum. Mol Biochem Parasitol (2006) 1.77
A 10 year study of the cause of death in children under 15 years in Manhiça, Mozambique. BMC Public Health (2009) 1.76
Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea. Am J Trop Med Hyg (2002) 1.73
Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells. Proc Natl Acad Sci U S A (2008) 1.73
Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets. PLoS One (2010) 1.73
Malaria in rural Mozambique. Part II: children admitted to hospital. Malar J (2008) 1.72
Sir2 paralogues cooperate to regulate virulence genes and antigenic variation in Plasmodium falciparum. PLoS Biol (2009) 1.72